EA202092696A1 - Лечение рака - Google Patents

Лечение рака

Info

Publication number
EA202092696A1
EA202092696A1 EA202092696A EA202092696A EA202092696A1 EA 202092696 A1 EA202092696 A1 EA 202092696A1 EA 202092696 A EA202092696 A EA 202092696A EA 202092696 A EA202092696 A EA 202092696A EA 202092696 A1 EA202092696 A1 EA 202092696A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
treating cancer
neutralizing agents
cancers
repair
Prior art date
Application number
EA202092696A
Other languages
English (en)
Inventor
Шаад Эсса Абдулла
Ашок Кумар Гупта
Сюян Сун
Original Assignee
Медиммун Лимитед
Иннейт Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед, Иннейт Фарма filed Critical Медиммун Лимитед
Publication of EA202092696A1 publication Critical patent/EA202092696A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Настоящее изобретение относится к применению средств, нейтрализующих NKG2A, и средств, нейтрализующих PD-1, для лечения видов рака, особенно видов рака, которые не характеризуются дефицитом репарации неспаренных оснований ДНК. Предусмотрены способы лечения рака, а также композиции и наборы, применимые для лечения рака, который не характеризуется дефицитом репарации неспаренных оснований ДНК.
EA202092696A 2018-05-15 2019-05-14 Лечение рака EA202092696A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671521P 2018-05-15 2018-05-15
PCT/EP2019/062305 WO2019219658A1 (en) 2018-05-15 2019-05-14 Treatment of cancer

Publications (1)

Publication Number Publication Date
EA202092696A1 true EA202092696A1 (ru) 2021-04-05

Family

ID=66752041

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092696A EA202092696A1 (ru) 2018-05-15 2019-05-14 Лечение рака

Country Status (12)

Country Link
US (1) US20210253694A1 (ru)
EP (1) EP3793607A1 (ru)
JP (1) JP2021523170A (ru)
KR (1) KR20210010486A (ru)
CN (1) CN112203691A (ru)
AU (1) AU2019270277A1 (ru)
CA (1) CA3099820A1 (ru)
EA (1) EA202092696A1 (ru)
MA (1) MA52627A (ru)
SG (1) SG11202011117VA (ru)
TW (1) TW202011989A (ru)
WO (1) WO2019219658A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004828A (zh) 2018-03-13 2020-11-27 依奈特制药公司 头颈癌的治疗
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
CN115516086A (zh) * 2020-05-13 2022-12-23 南京传奇生物科技有限公司 类猿icp47及变体减少同种异体细胞宿主排斥的组合物及方法
WO2023284874A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
AR127234A1 (es) * 2021-10-04 2024-01-03 Servier Lab Terapia del cáncer dirigida a nkg2a

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU2003232456B2 (en) 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
RU2499001C2 (ru) 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
EP2247619A1 (en) 2008-01-24 2010-11-10 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
CA2959318A1 (en) * 2014-08-28 2016-03-03 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
KR20230088521A (ko) * 2014-09-16 2023-06-19 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
CA3007671A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
HUE054356T2 (hu) * 2016-01-21 2021-09-28 Innate Pharma Gátlási reakcióutak semlegesítése limfocitákban

Also Published As

Publication number Publication date
MA52627A (fr) 2021-03-24
SG11202011117VA (en) 2020-12-30
CA3099820A1 (en) 2019-11-21
JP2021523170A (ja) 2021-09-02
KR20210010486A (ko) 2021-01-27
CN112203691A (zh) 2021-01-08
TW202011989A (zh) 2020-04-01
WO2019219658A1 (en) 2019-11-21
AU2019270277A1 (en) 2021-01-07
EP3793607A1 (en) 2021-03-24
US20210253694A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
EA202092696A1 (ru) Лечение рака
CL2022001671A1 (es) Inhibidores de sos1
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MD3788040T2 (ro) Piridazinone în calitate ca inhibitori de PARP7
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
EA202090179A1 (ru) Композиции и способы модуляции роста волос
MX2022004513A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
MX2020008767A (es) Disruptores del dímero egfr y uso de estos.
PH12019502602A1 (en) Polypeptides antagonizing wnt signaling in tumor cells
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MD3728207T2 (ro) Chinazolinone ca inhibitori PARP14
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2022000310A (es) Inhibidores de proteina bcl-2.
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
BR112021017661A2 (pt) Uso de compostos 8,9-di-hidrocanabidiol
EA202092136A1 (ru) Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
WO2019023315A3 (en) RAC INHIBITORS
CO2023010694A2 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
EA202090855A1 (ru) Композиции и способы модуляции роста волос
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.